



COPY OF PAPERS
ORIGINALLY FILED

RCE/1600

PTO/SB/30 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

Application Number	09/478,668
Filing Date	January 6, 2002
First Named Inventor	Bannon, et al.
Art Unit	1644
Examiner Name	Huynh, P.
Attorney Docket Number	2002834-0058 (CIP4 DIV)

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- iii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other _____

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 03-1721
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other _____
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Brenda Herschbach Jarrell	Registration No. (Attorney/Agent)	39,223
Signature		Date	June 18, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Kimberly A. Young	Date	6/18/02
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

07/02/2002 SSITHIB1 00000137 031721 09478668

07/02/2002 SSITHIB1 00000137 09478668
02 FC:279 370.00 CH

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900



COPY OF PAPERS
ORIGINALLY FILED

ATTORNEY DOCKET NUMBER: 2002834-0058 (CIP4 DIV/Modified Allergens)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bannon, et al.
Serial No.: 09/478,668
Filed: January 6, 2000
For: METHODS AND REAGENTS FOR DECREASING CLINICAL REACTIONS
TO ALLERGY

Examiner: Huynh, P.
Art Unit: 1644
Group: 1640

Assistant Commissioner for Patents
Washington, DC 20231
BOX AF

23/D
RECEIVED
JUL 11 2002
TECH CENTER 1600/2900

Hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to: Assistant
Commissioner For Patents, Washington D.C. 20231
on June 18, 2002
[Signature]

RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.116

Sir:

In response to the Final Office Action mailed December 18, 2001, Applicant respectfully requests entrance of the following Amendment into the case, and consideration of the following Remarks.

Amendment

In the claims:

Please amend claims 37-42, 46, 47, 51, and 53 to read as follows:

37. A modified protein allergen whose amino acid sequence is substantially identical to that of an unmodified protein allergen except that at least one amino acid has been modified in at least one IgE epitope so that IgE binding to the modified protein allergen is reduced as compared with IgE binding to the unmodified protein allergen, the at least one IgE epitope being one that is recognized when the unmodified protein allergen is contacted with serum IgE from an individual that is allergic to the unmodified protein allergen.
38. The modified protein allergen of claim 37 wherein at least one amino acid has been modified in all the IgE epitopes of the unmodified protein allergen.

Docket No.: 2002834-0058

Page 1 of 24

USSN: 09/478,668

08/01/2002 GDUCKETT 00000005 031721 09478668

01 FC:202 42.00 CH
02 FC:203 252.00 CH
03 FC:204 140.00 CH